Results 291 to 300 of about 205,027 (361)

CD59, Disulphide‐Locked Human C9 and Horse C9 Inhibit Human Membrane Attack Complex Assembly by Similar Mechanisms

open access: yesImmunology, Volume 176, Issue 3, Page 363-372, November 2025.
The membrane attack complex (MAC) is formed by the stepwise assembly of five proteins: C5b, C6, C7, C8 and C9. MAC plays a key role in driving inflammation in numerous diseases. This study compares the inhibitory mechanisms of MAC assembly by soluble CD59 (sCD59), a disulphide‐locked C9 mutant (C9lock) and horse C9 (HoC9).
Rebekah S. Cooke   +5 more
wiley   +1 more source

Quantitative analysis of human umbilical vein endothelial cell morphology and tubulogenesis

open access: yesJournal of Microscopy, Volume 300, Issue 2, Page 234-249, November 2025.
Abstract Primary human umbilical vein endothelial cells can grow as both a monolayer in culture and also as a capillary‐like network making them an ideal model system in order to study vascular remodelling. Image‐based analysis can allow assessment of cell morphology and motility but is dependent on accurate cell segmentation which requires high ...
Viviane Mignone   +6 more
wiley   +1 more source

Pharmacotherapy for Age-Related Macular Degeneration

open access: yesJournal of Ophthalmic & Vision Research, 2008
Hamid Ahmadieh
doaj  

Early-onset macular drusen, a monogenic form of age-related macular degeneration. [PDF]

open access: yesAm J Ophthalmol Case Rep
George LM   +8 more
europepmc   +1 more source

Treatment of age-related macular degeneration

open access: yesThe Lancet, 2013
Chui Ming Gemmy Cheung, Tien Yin Wong
openaire   +3 more sources

Pigment Epithelium‐Derived Factor (PEDF)‐Based Therapy Induced Photoreceptor Survival by Stabilizing Choroidal Neovessels in a VEGF Overexpression CNV Rat Model

open access: yesThe FASEB Journal, Volume 39, Issue 19, 15 October 2025.
Stabilizing choroidal neovessels offers a novel treatment‐option for pathological CNV. Pigment epithelium‐derived factor (PEDF), a multifunctional protein with vessel‐stabilizing properties, is a promising candidate for this approach. Its efficacy with and without bevacizumab was tested in a VEGF overexpression CNV rat model.
Alexander V. Tschulakow   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy